OncLive TV

Dr. Lam Discusses Agents for ROS1-Mutated NSCLC

November 3rd 2017

Vincent Lam, MD, assistant professor, The University of Texas MD Anderson Cancer, discusses agents to target ROS1-mutated non-small cell lung cancer (NSCLC).

Dr. Bouvet on Remaining Challenges With Thyroid Cancer Surgery

November 3rd 2017

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses the remaining challenges with thyroid cancer surgery.

Dr. Sacco on Upfront Treatments for Head and Neck Cancer

November 3rd 2017

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.

Dr. Maloney on Future Treatment With CAR T-Cell Therapy

November 3rd 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Dr. Califano on the Future of Surgery in Head and Neck Cancer

November 3rd 2017

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the future of surgery in head and neck cancer.

Dr. Stadtmauer on Current Challenges With Multiple Myeloma

November 3rd 2017

Dr. Perl on the Outlook of FLT3 Inhibitors for AML

November 3rd 2017

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

Dr. Epperla on Treatment Following Ibrutinib in MCL

November 1st 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

Dr. Aggarwal on the Future of ADT for Patients With Prostate Cancer

November 1st 2017

Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.

Dr. Maloney Discusses CAR T-Cell Therapy in Solid Tumors

November 1st 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses using CAR T-cell therapy in solid tumors.

Dr. Armstrong Discusses Hereditary Prostate Cancer

November 1st 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Dr. Camidge Discusses Unmet Needs in ALK+ Lung Cancer

November 1st 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.

Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer

November 1st 2017

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Dr. Geynisman on Patient Preferences for Treatment of RCC

November 1st 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

Dr. Bekaii-Saab on the Response Rate of Pembrolizumab in MSI-H CRC

November 1st 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the response rate of pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Dr. Berry on LHRH Antagonists Versus Agonists for Prostate Cancer

November 1st 2017

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Dr. Friedlander on Checkpoint Inhibitors in Second-Line Bladder Cancer Treatment

October 31st 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.

Dr. Cooperberg on Ongoing Trials in Early Prostate Cancer

October 31st 2017

Matthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.

Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC

October 31st 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.

Dr. Awan Discusses Combinations With Ibrutinib in CLL

October 31st 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.